Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
7%
All Cause Mortality
9%
Androgen
9%
Anemia
8%
Bevacizumab
18%
Bleeding
9%
Breast Cancer
9%
Cancer Mortality
10%
Carcinoma
9%
Cardiovascular System Cancer
6%
Congestive Heart Failure
18%
Endometrium Cancer
9%
Everolimus
6%
Hepatotoxicity
5%
Lymphocytopenia
5%
Malignant Neoplasm
28%
Mammalian Target of Rapamycin Inhibitor
22%
Metabolic Syndrome X
15%
Neoplasm
9%
Neutropenia
8%
Observational Study
14%
Phase II Trials
5%
Phase III Trials
5%
Prevalence
6%
Prospective Cohort Study
16%
Prospective Study
7%
Prostate Cancer
9%
Protein Tyrosine Kinase
56%
Protein Tyrosine Kinase Inhibitor
49%
Random Effects Model
13%
Randomized Clinical Trial
19%
Randomized Controlled Trial
13%
Renal Cell Carcinoma
26%
Sorafenib
26%
Sunitinib
27%
Temsirolimus
6%
Thrombocytopenia
8%
Thromboembolism
10%
Vandetanib
5%
Vasculotropin
5%
Vasculotropin Receptor
47%
Vitamin D
9%
Medicine and Dentistry
Acrylamide
9%
Alcohol Consumption
13%
Arm
7%
Biliary Tract Disease
9%
Bleeding
9%
Body Mass Index
13%
Cardiometabolic Risk
9%
Clear Cell Renal Cell Carcinoma
20%
Cohort Effect
5%
Cohort Studies
8%
Colitis
5%
Colorectal Carcinoma
13%
Congestive Heart Failure
9%
Cross Sectional Study
10%
Cytotoxic T-Cell
9%
Depressive Disorder
10%
Homeostatic Model Assessment
6%
Immune Checkpoint Inhibitor
9%
Immune-Related Adverse Events
9%
Ipilimumab
5%
Logistic Regression Analysis
8%
Malignant Neoplasm
7%
Mammalian Target of Rapamycin Inhibitor
13%
Meta-Analysis
100%
Metabolic Syndrome
15%
Nurse
6%
Observational Study
12%
Odds Ratio
28%
Programmed Cell Death
9%
Programmed Death 1 Ligand 1
9%
Prospective Cohort Study
46%
Prospective Study
16%
Protein Tyrosine Kinase
19%
Pyridoxal 5 Phosphate
9%
Pyridoxine
9%
Random Effects Model
15%
Sorafenib
9%
Sunitinib
18%
Tyrosine-Kinase Inhibitor
19%
Uterine Cancer
27%
Vasculotropin Receptor
18%
Nursing and Health Professions
Body Mass
5%
Cancer Incidence
6%
Cancer Mortality
5%
Colorectal Carcinoma
9%
Confidence Interval
24%
Depressive Disorder
11%
Logistic Regression Analysis
10%
Meta Analysis
40%
Metabolic Syndrome X
12%
Odds Ratio
11%
Prevalence
7%
Prospective Cohort Study
25%
